Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Genetic barrier to antiretroviral drug-resistance. Focus on raltegravir, the first integrase inhibitor].

Medecine et maladies infectieuses - 1 Sept 2010

Delaugerre C

Abstract excerpt

The genetic barrier for the antiretroviral describes the ability to select resistant viruses to this antiretroviral when the viral replication is not controlled. This includes combining several concepts: (1) the number of nucleotide changes required for a resistance mutation, (2) the impact of this mutation on the level of susceptibility to antiretroviral (3) the impact of this mutation on viral replication...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Interactions
Share to Drug Resistance, Multiple, Viral
Share to Genes, pol

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to HIV Integrase

Share to HIV Integrase Inhibitors

Share to Pyrrolidinones

Share to Raltegravir Potassium

Source

Identifiers

PMID: 20800182
DOI: 10.1016/S0399-077X(10)70001-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Genetic barrier to antiretroviral drug-resistance. Focus on raltegravir, the first integrase inhibitor].PMID 20800182Read ↗

HIV-1 antiretroviral resistance: scientific principles and clinical applications.Semantic proximity Read ↗

[Resistance to antiretroviral agents: mechanism and study methods].Semantic proximity Read ↗

HIV-1 Integrase Inhibitor Resistance and Its Clinical ImplicationsSemantic proximity Read ↗

Clinical benefit of dolutegravir in HIV-1 management related to the high genetic barrier to drug resistance.Semantic proximity Read ↗

[Resistance to integrase inhibitors].Semantic proximity Read ↗

Perspectives on the Barrier to Resistance for Dolutegravir + Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 InfectionSemantic proximity Read ↗

[Viral resistance and genetic barrier of atazanavir].Semantic proximity Read ↗

HIV-1 integrase resistance among antiretroviral treatment naive and experienced patients from Northwestern Poland.Semantic proximity Read ↗

Genetic barrier to the development of resistance to integrase inhibitors in HIV-1 subtypes CRF01_AE and B.Semantic proximity Read ↗

Dolutegravir resistance mutations: lessons from monotherapy studies.Semantic proximity Read ↗

[Etravirine: genetic barrier and resistance development].Semantic proximity Read ↗

International perspectives on antiretroviral resistance. Nucleoside reverse transcriptase inhibitor resistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.